4.6 Review

CD133: A cancer stem cells marker, is used in colorectal cancers

期刊

WORLD JOURNAL OF GASTROENTEROLOGY
卷 19, 期 17, 页码 2603-2611

出版社

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v19.i17.2603

关键词

CD133; Colorectal cancer; Cancer stem cells; Prognosis; Chemoradiotherapy resistance

资金

  1. Clinical Key Discipline Fund by Ministry of Health
  2. Chinese National Clinical Key Discipline
  3. Shanghai Science and Technology Commission of Shanghai Municipality [10DJ1400500]

向作者/读者索取更多资源

Colorectal cancer is one of the most common malignant tumors worldwide. A model of cancer development involving cancer stem cells has been put forward because it provides a possible explanation of tumor hierarchy. Cancer stem cells are characterized by their proliferation, tumorigenesis, differentiation, and self-renewal capacities, and chemoradiotherapy resistance. Due to the role of cancer stem cells in tumor initiation and treatment failure, studies of cancer stem cell markers, such as CD133, have been of great interest. CD133, a five-transmembrane glycoprotein, is widely used as a marker to identify and isolate colorectal cancer stem cells. This marker has been investigated to better understand the characteristics and functions of cancer stem cells. Moreover, it can also be used to predict tumor progression, patient survival, chemoradiotherapy resistance and other clinical parameters. In this review, we discuss the use of CD133 in the identification of colorectal cancer stem cell, which is currently controversial. Although the function of CD133 is as yet unclear, we have discussed several possible functions and associated mechanisms that may partially explain the role of CD133 in colorectal cancers. In addition, we focus on the prognostic value of CD133 in colorectal cancers. Finally, we predict that CD133 may be used as a possible target for colorectal cancer treatment. (C) 2013 Baishideng. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据